Clinical Trial Update: LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LC-Plasma for immune-response modulation and reduction of symptoms in upper respiratory tract infections has completed. No efficacy or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Respiratory Tract Infection

Drugs mentioned

• LC-Plasma

Snippet

Sponsor: RDC Clinical Pty Ltd | Conditions: Healthy Volunteer, Immune Response | Phase 3 | Status: COMPLETED